In 2022, KDIGO’s diabetes in CKD guidelines recommended long-acting GLP-1 RAs for T2D patients with CKD who need additional glycemic or weight control despite metformin and an SGLT2 inhibitor [68]. The gene discussed is GLP1R; the disease is chronic kidney disease.